Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review.
Ziyu Kuang, Yuansha Ge, Luchang Cao...
https://pubmed.ncbi.nlm.nih.gov/39066853/Actively Recruiting
Led by Fatih GURLER · Updated on 2026-09-16
100
Participants Needed
1
Research Sites
15 weeks
Total Duration
Researchers are evaluating cardiac side effects in women with early-stage breast cancer who receive systemic chemotherapy andor anti-HER2 therapy as part of their usual cancer care. The study aims to determine if changes in Global Longitudinal Strain GLS on echocardiography can detect early heart dysfunction before a drop in left ventricular ejection fraction LVEF. It also investigates whether changes in circulating microRNA levels relate to early cardiac dysfunction and if cardiotoxicity occurs more often with anthracycline-containing chemotherapy compared to anthracycline-free treatments. Participants receive standard chemotherapy andor anti-HER2 therapy as determined by their oncologist. The study does not alter treatment selection, dose, or duration. Patients are grouped by chemotherapy regimen for comparison. Assessments occur at four time points before treatment, and at 3, 6, and 12 months after starting therapy. These include echocardiography measuring LVEF, GLS, and other heart function parameters, blood samples for microRNA and cardiac biomarker analysis, and quality of life questionnaires. Participants undergo transthoracic echocardiography and blood draws aligned with their routine care visits, providing samples for microRNA and cardiac biomarker testing. They complete various patient-reported outcome questionnaires assessing quality of life, fatigue, sexual health, anxietydepression, sleep quality, and cognitive function. The study monitors adverse events and tracks cardiac dysfunction incidence over 12 months to better understand early cardiac effects and identify patients at higher risk during systemic breast cancer treatment.
CONDITIONS
Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer
S
Sıla Soylu Koçoğlu, MD
F
Fatih Gürler, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fatih GURLER
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 months
Participants undergo echocardiography, blood sample collections, and quality of life questionnaires at baseline, 3, 6, and 12 months while receiving their standard cancer therapy.
4 visits at baseline, Month 3, Month 6, and Month 12
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Ziyu Kuang, Yuansha Ge, Luchang Cao...
https://pubmed.ncbi.nlm.nih.gov/39066853/Nattaya Poovorawan, Thiti Susiriwatananont, Chinachote Teerapakpinyo...
https://pubmed.ncbi.nlm.nih.gov/40270054/Alexander R Lyon, Teresa López-Fernández, Liam S Couch...
https://pubmed.ncbi.nlm.nih.gov/36017568/Albulena Mecinaj, Geeta Gulati, Anne Hansen Ree...
https://pubmed.ncbi.nlm.nih.gov/38510299/Riccardo Bernasconi, Gabriela M Kuster
https://pubmed.ncbi.nlm.nih.gov/38802331/Hanne M Boen, Martina Cherubin, Constantijn Franssen...
https://pubmed.ncbi.nlm.nih.gov/38774014/Fatih GURLER
Lead Sponsor